How Reservoir launched on X

Reservoir is a consumer immune cell preservation service that collects, isolates, and cryogenically stores a person's peripheral blood mononuclear cells (the T cells, B cells, natural killer cells, and monocytes that make up adaptive immunity) through a single 15-minute blood draw. It is aimed at adults who want to bank biological material now, on the premise that today's cells carry less accumulated damage than the ones they will have a decade from now, and that stored samples could become useful as personalized cell therapies mature. The launch matters because, until now, this kind of long-term cellular banking has largely been limited to research settings, cord blood for newborns, or private arrangements for the wealthy. The service is run out of partner clinics and, in select U.S. cities, through an at-home phlebotomist visit. Samples are processed, cryopreserved, and stored below −150°C in an FDA-registered facility under the member's name, with release only on the member's instruction in coordination with a licensed physician. Pricing starts around $5,000 with an annual storage fee of roughly $270, positioning Reservoir somewhere between egg freezing and cord blood banking in both price and intent. Reservoir is a subsidiary of Cellino, the Cambridge, Massachusetts biotech developing autonomous manufacturing for personalized iPSC-based cell therapies. It is led by Cellino co-founders Nabiha Saklayen, PhD (CEO) and Marinna Madrid, PhD (Chief Product and Regulatory Officer), who started the parent company in 2017 after research at Harvard. The launch is announced in partnership with Vinod Khosla, whose Khosla Ventures is an existing Cellino backer, signaling that the team sees consumer cell banking as the near-term on-ramp to a longer bet on patient-specific regenerative medicine.